Immunosuppressive therapies increase the susceptibility of patients to infections. The current pandemic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compels clinicians to develop recommendations for successful clinical management and surveillance of immunocompromised patients at high risk for severe disease progression. With only few case studies published on SARS-CoV-2 infection in patients with rheumatic diseases, we report a 25-year-old male who developed moderate coronavirus disease 2019 (COVID-19) with fever, mild dyspnea, and no major complications despite having received high-dose prednisolone, cyclophosphamide, and rituximab for the treatment of highly active, life-threatening eosinophilic granulomatosis with polyangiitis (EGPA).
Keywords: COVID-19; EGPA; SARS-CoV-2; cyclophosphamide; eosinophilic granulomatosis with polyangiitis; immunosuppression; rituximab; vasculitis.
Copyright © 2020 Schramm, Venhoff, Wagner, Thiel, Huzly, Craig-Mueller, Panning, Hengel, Kern and Voll.